DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer

Nature Reviews Clinical Oncology

Volumn 7, Issue 3, 2010, Pages 174-177

  Sinicrope, Frank A ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; GENE MUTATION; HUMAN; MISMATCH REPAIR; NOTE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; HUMANS; TREATMENT OUTCOME;

EID: 77749277597     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.235     Document Type: Note

References (35)

1. Ionov, Y., peinado, M. A., Malkhosyan, S., Shibata, D. & perucho, M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363, 558-561 (1993).
2. Poynter, J. N. et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol. Biomarkers Prev. 17, 3208-3215 (2008).
3. Piñol, V. et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293, 1986-1994 (2005).
4. Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681-8686 (1999).
5. Thibodeau, S. N., Bren, G. & Schaid, D. Microsatellite instability in cancer of the proximal colon. Science (New York, NY) 260, 816-819 (1993).
6. Jass, J. R. et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42, 673-679 (1998).
7. Lindor, N. M. et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol. 20, 1043-1048 (2002).
8. Boland, C. R. et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58, 5248-5257 (1998).
9. Herman, J. G. et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA 95, 6870-6875 (1998).
10. Sinicrope, F. A. et al. prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131, 729-737 (2006).
11. Gafà, R. et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89, 2025-2037 (2000).
12. Halling, K. C. et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J. Natl Cancer Inst. 91, 1295-1303 (1999).
13. Lanza, G. et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J. Clin. Oncol. 24, 2359-2367 (2006).
14. Samowitz, W. S. et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomarkers Prev. 10, 917-923 (2001).
15. Popat, S., Hubner, R. & Houlston, R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23, 609-618 (2005).
16. Kerr, D. J. et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract]. J. Clin. Oncol. 27 (Suppl. 15S), a4000 (2009).
17. Lamberti, C. et al. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int. J. Colorectal Dis. 22, 145-152 (2007).
18. Kim, G. P. et al. prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel project Collaborative Study. J. Clin. Oncol. 25, 767-772 (2007).
19. Benatti, P. et al. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 11, 8332-8340 (2005).
20. Ribic, C. M. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257 (2003).
21. Jover, R. et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 45, 365-373 (2009).
22. Carethers, J. M. et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117, 123-131 (1999).
23. Arnold, C. N., Goel, A. & Boland, C. R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer 106, 66-73 (2003).
24. Hemminki, A., Mecklin, J. P., Jarvinen, H., Aaltonen, L. A. & Joensuu, H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119, 921-928 (2000).
25. Elsaleh, H. et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355, 1745-1750 (2000).
26. Sargent, D. J. et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials [abstract]. J. Clin. Oncol. 26 (Suppl.), a4008 (2008).
27. Bertagnolli, M. M. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B protocol 89803. J. Clin. Oncol. 27, 1814-1821 (2009).
28. Tejpar, S. B. et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-Lv or 5FU-Lv and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) [abstract]. J. Clin. Oncol. 27 (Suppl. 15S), a4001 (2009).
29. Saltz, L. B. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25, 3456-3461 (2007).
30. de Gramont, A. et al. Oxaliplatin/5FU/Lv in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a medial follow-up of six years. J. Clin. Oncol. 25 (Suppl. 18S), a4007 (2007).
31. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013-2019 (2008).
32. Sinicrope, F. A. et al. Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer (in press).
33. Barrow, E., McMahon, R., Evans, D. G., Levine, E. & Hill, J. Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. Br. J. Surg. 95, 868-875 (2008).
34. Deng, G. et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 10, 191-195 (2004).
35. Domingo, E. et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet. 41, 664-668 (2004).